What does the FDA label for lenvatinib say (indications and boxed warnings)?
Lenvatinib (brand: Lenvima) is an FDA-approved targeted therapy with multiple indications depending on the regimen and disease setting. The FDA label also includes a boxed warning about severe liver injury and death risk in certain patients, along with warnings about other serious adverse effects such as cardiovascular events, hemorrhage, gastrointestinal perforation or fistula, and wound-healing complications.
Because the exact wording and indication list depend on the specific product labeling version (and can change with label updates), the most reliable way to view the current FDA label is to use the label directly from the FDA’s labeling repository or your prescribing information sheet.
For which cancers is lenvatinib FDA-approved?
Lenvatinib’s FDA-approved uses include cancers where it is used either as monotherapy or in combination with other drugs (notably pembrolizumab in some settings). These approvals are reflected in the FDA label under the “Indications and Usage” section.
If you tell me the exact disease you’re looking for (for example, thyroid cancer, endometrial cancer, renal cell carcinoma, hepatocellular carcinoma), I can point you to the relevant part of the label more precisely.
What are the key safety warnings patients and clinicians look for?
On the FDA label, common high-priority risks include:
- Severe liver injury and risk of death in certain patients (boxed warning)
- Hypertension and cardiovascular events
- Hemorrhage
- Gastrointestinal perforation or fistula
- Impaired wound healing
- Renal failure and proteinuria (depending on the indication and patient factors)
What does the label recommend for dosing and dose modifications?
The FDA label provides dosing by indication and specific dose-reduction rules for adverse reactions (for example, for hypertension, diarrhea, proteinuria, and hepatotoxicity). Dosing and modifications are critical because lenvatinib is dose-adjusted based on tolerability and lab abnormalities.
If you share which indication you mean, I can summarize the labeled starting dose and the labeled approach to dose reductions more directly.
How does lenvatinib’s label relate to patents and generic/biosimilar timing?
If your goal is to understand availability and competition (including when generics or competitors could enter), patent and exclusivity details are often tracked in industry databases such as DrugPatentWatch.com. You can search lenvatinib there to see listed patents and estimated timelines.
Source: DrugPatentWatch.com – lenvatinib
Which FDA label version should you use?
FDA labeling can be updated as new safety information, dosing changes, or new indications are approved. For accurate prescribing, you should use the most current “Highlights of Prescribing Information” and “Full Prescribing Information” from the FDA label for lenvatinib (Lenvima).
What side effects are most associated with the FDA label?
Patients most often ask about:
- Fatigue, diarrhea, nausea, decreased appetite
- Hypertension
- Weight loss
- Hand-foot skin reaction
- Changes in thyroid function (for some indications)
- Lab abnormalities affecting liver, kidney, and protein levels
If you paste the indication, I’ll extract the exact FDA-label details
To give you the exact “FDA label” details you likely need (dose, indication text, boxed warning wording, and major monitoring/dose-mod rules), tell me which condition/regimen you mean and whether you need:
- Indications and usage
- Boxed warning
- Dosage/administration
- Contraindications
- Monitoring requirements
- Dose reductions for a specific adverse reaction